Vivani Medical (VANI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
The annual meeting will be held virtually on June 24, 2026, with shareholders able to vote online, by phone, mail, or during the webcast.
Four main proposals are up for vote: election of six directors, advisory approval of executive compensation, approval of the amended 2022 Omnibus Incentive Plan, and ratification of BPM LLP as auditor.
The board recommends voting in favor of all proposals and emphasizes the importance of shareholder participation.
Voting matters and shareholder proposals
Shareholders will vote on electing six directors, approving executive compensation, amending the 2022 Omnibus Incentive Plan, and ratifying BPM LLP as auditor.
The board recommends voting FOR all proposals.
Shareholders can submit proposals for the 2027 meeting by December 30, 2026, and must follow specific procedures for director nominations.
Board of directors and corporate governance
The board consists of six members, with one female director and a focus on diverse backgrounds and skills.
All directors except the CEO and his father are independent under Nasdaq rules.
Three standing committees: Audit, Compensation, and Nominating & Corporate Governance, all meeting independence standards.
The board has adopted policies on insider trading, director diversity, and compensation recovery.
Latest events from Vivani Medical
- Virtual meeting to elect directors, approve pay, incentive plan, and auditor for 2026.VANI
Proxy filing29 Apr 2026 - Long-acting GLP-1 implants promise improved adherence and outcomes in obesity care.VANI
Corporate presentation26 Mar 2026 - Advanced semaglutide implant program and secured funding to support operations into mid-2027.VANI
Q4 202526 Mar 2026 - A once or twice-yearly GLP-1 implant targets adherence and access gaps in chronic disease care.VANI
2025 ThinkEquity Conference3 Feb 2026 - Long-acting implant technology targets improved adherence and outcomes in obesity and diabetes.VANI
H.C. Wainwright 26th Annual Global Investment Conference 202420 Jan 2026 - Long-acting GLP-1 implant targets improved adherence, with Phase I data expected by mid-2025.VANI
Maxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026 - First-in-human trial of a six-month GLP-1 implant underway, with results expected mid-year.VANI
Emerging Growth Virtual Conference 7810 Jan 2026 - Proprietary drug implants show promise for obesity and diabetes, with key data expected mid-year.VANI
Emerging Growth Virtual Conference19 Dec 2025 - Semaglutide implant targets long-term adherence and tolerability in obesity care, with trials imminent.VANI
Emerging Growth Conference 202517 Dec 2025